Wellcome Trust Conference Centre, Hinxton, Cambridge, UK
28th - 30th September 2008
Viral vector vaccines represent one of the most rapidly growing areas in vaccine development. Many vaccines in clinical development for major global infectious diseases, HIV, tuberculosis and malaria, are viral vectors. In the cancer field at least two viral vector products are in phase III licensure trials. Viral vector vaccines for animals are already on the market, mainly avipox vector vaccines for companion animals, but livestock vaccines are in development. Finally, therapeutic vaccines for the immunotherapy of viral infections are in clinical trials, with early evidence of efficacy. However, these fields have been developing with limited contact. This meeting will encompass all these areas and address common challenges in taking this technology to licensure. The aims are to review and discuss recent progress, assess safety and manufacturing issues and identify common priorities for accelerated development. Scientific Programme Committee:Martin Friede – World Health OrganisationAdrian Hill - The Jenner Institute
|
|